Biotricity reports Q4 EPS (47c) vs. (56c) last year

Reports Q4 revenue $3.2M vs. $2.7M last year. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “Fiscal 2024 has been a year of massive transformation for Biotricity. We have harnessed the power of workflow automation, AI technology, and further technological enhancements to drive substantial improvements in our operational expenses, margins, and revenues. This year, we demonstrated our ability to scale efficiently while maintaining high-quality service, putting us firmly on the path to EBITDA breakeven and profitability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 500 billion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability and pave the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model by the end of 2024. Our addition of multiple Group Purchasing Organizations and other strategic alliances during the fourth quarter has positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America. These partnerships, which collectively represent 97% of U.S. hospitals, leverage significant negotiating power to secure advantageous terms for medical devices and supplies, strengthening our position as a player in the healthcare technology sector. Moreover, the Health Canada approval for Biocore in February has opened new avenues for revenue growth in the $1.56 billion Canadian cardiology devices market. These developments mark a significant leap forward in our mission to deliver innovative, accessible, and high-quality cardiac care solutions.”